SanaCurrents applies data points to assess how likely a company will be able to advance a drug or device, helping us to determine our decision to potentially buy the stock, which we disclose to members.

Account Information







Twitter Username (optional, but highly recommended for Premium Alerts)



Billing Details

Visa, Master Card, American Express, Discover




Billing Address







Shipping Address


Shipping is the same as billing

SanaCurrents Annual Special

SanaCurrents Annual Special Rate

SanaCurrents BioTech Probability Sentiment.
Current limited time special offer includes:
* Full SanaCurrents Access
* Full GeoInvesting Portal Access
* Special Report – “Gain Confidence by Investing in Recurring Revenue Stocks”
* Special Report – “FDA Creating New Investment Opportunities in BioTech Stocks”
For $7.99, you get a month to decide if you want to continue with the service at your discounted rate of $997, a 76% discount off the the annual service, normally valued at $4,200! Your discounted annual payment will not be processed until your 30 day trial ends. You can easily cancel any time within your trial period. You can do this at your premium member account page.

    • Product Price: 30 day trial for $7.99, $997.00/year
  • Today’s Charge:

Submit Order


SanaCurrents Leaves Your BioTech Guesswork Behind

  • 3 hand selected biotech ideas per month with positive outcome Probability Sentiments
  • Brief 1 to 2 page abstract outlining each pitch
  • The “Edge” that we believe will catalyze the performance of the stock
  • Updates leading up to important company dates and events on our radar

What were some of the key approaches that led to SanaCurrents’ successful case studies?

  • Identifying the timing of binary events to determine when a stock will move.
  • Evaluating the track record of success in early trials of drug candidates.
  • Finding the management that is interested in advancing the a drug to approval – which often leads to a significant increase in stock value – instead of management that has been capitalized to fund exploratory research.
  • Determining the support of key opinion leaders for a specific drug or device.
  • Looking at past FDA actions.